喀斯瑪商城-第三方B2B電子商務(wù)平臺

AMPA Receptor 4 (GluA 4) (D41A11) XP Rabbit mAb

商城價：登錄可見

品牌：CST/賽信通

貨號：8070T

規(guī) 格：

運費：登錄后可查看運費

DeepBio得分:

DeepBio得分是基于文獻(xiàn)引用次數(shù)，影響因子，文獻(xiàn)新近度等因素計算的客觀產(chǎn)品評級，得分越高表明該產(chǎn)品經(jīng)過越可靠的實驗驗證，質(zhì)量可信度越高

2家供應(yīng)商在售
商品名稱	規(guī)格	代理級別	價格	運費	供應(yīng)商	購買
AMPA Receptor 4 (GluA 4) (D41A11) XP ? Rabbit mAb 交貨周期:現(xiàn)貨	20 μl	經(jīng)銷	登錄可見	-	北京敏泰元科技有限公司	- + 立即購買庫存：20
CST 8070T AMPA Receptor 4(GluA 4)(D41A11)XP Rabbit mAb 交貨周期:部分現(xiàn)貨，期貨3-4周左右，優(yōu)質(zhì)售后	20μl	經(jīng)銷	登錄可見	-	上海優(yōu)寧維生物科技股份有限公司	- + 立即購買庫存：999

產(chǎn)品詳情

文獻(xiàn)引用

文獻(xiàn)圖片

實驗數(shù)據(jù)

應(yīng)用：W, IP, IF-F
AMPA- (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), kainate-, and NMDA- (N-methyl-D-aspartate) receptors are the three main families of ionotropic glutamate-gated ion channels. AMPA receptors (AMPARs) are comprised of four subunits (GluR 1-4), which assemble as homo- or hetero-tetramers to mediate the majority of fast excitatory transmissions in the central nervous system. AMPARs are implicated in synapse formation, stabilization, and plasticity (1). In contrast to GluR 2-containing AMPARs, AMPARs that lack GluR 2 are permeable to calcium (2). Post-transcriptional modifications (alternative splicing, nuclear RNA editing) and post-translational modifications (glycosylation, phosphorylation) result in a very large number of permutations, fine-tuning the kinetic properties of AMPARs. Research studies have implicated activity changes in AMPARs in a variety of diseases including Alzheimer’s, amyotrophic lateral sclerosis (ALS), stroke, and epilepsy (1).GluR 4 containing AMPARs are found in synapses and GluR 4 delivery to synapses and cell surface expression is mediated through phosphorylation of Ser842 by PKA or PKC (3).

Supporting Data

REACTIVITY	H M R
SENSITIVITY	Endogenous
MW (kDa)	100
Source/Isotype	Rabbit IgG

Application Key:

W-Western
IP-Immunoprecipitation
IHC-Immunohistochemistry
ChIP-Chromatin Immunoprecipitation
IF-Immunofluorescence
F-Flow Cytometry
E-P-ELISA-Peptide

Species Cross-Reactivity Key:

H-Human
M-Mouse
R-Rat
Hm-Hamster
Mk-Monkey
Vir-Virus
Mi-Mink
C-Chicken
Dm-D. melanogaster
X-Xenopus
Z-Zebrafish
B-Bovine
Dg-Dog
Pg-Pig
Sc-S. cerevisiae
Ce-C. elegans
Hr-Horse
All-All Species Expected

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:50
Immunofluorescence (Frozen)	1:400

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

AMPA Receptor 4 (GluA 4) (D41A11) XP^? Rabbit mAb detects endogenous levels of total GluA 4 protein.

Species Reactivity:

Human, Mouse, Rat

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln890 of human GluA 4 protein.

Background

AMPA- (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), kainate-, and NMDA- (N-methyl-D-aspartate) receptors are the three main families of ionotropic glutamate-gated ion channels. AMPA receptors (AMPARs) are comprised of four subunits (GluR 1-4), which assemble as homo- or hetero-tetramers to mediate the majority of fast excitatory transmissions in the central nervous system. AMPARs are implicated in synapse formation, stabilization, and plasticity (1). In contrast to GluR 2-containing AMPARs, AMPARs that lack GluR 2 are permeable to calcium (2). Post-transcriptional modifications (alternative splicing, nuclear RNA editing) and post-translational modifications (glycosylation, phosphorylation) result in a very large number of permutations, fine-tuning the kinetic properties of AMPARs. Research studies have implicated activity changes in AMPARs in a variety of diseases including Alzheimer’s, amyotrophic lateral sclerosis (ALS), stroke, and epilepsy (1).

GluR 4 containing AMPARs are found in synapses and GluR 4 delivery to synapses and cell surface expression is mediated through phosphorylation of Ser842 by PKA or PKC (3).

Palmer, C.L. et al. (2005) Pharmacol Rev 57, 253-77.
Cull-Candy, S. et al. (2006) Curr Opin Neurobiol 16, 288-97.
Gomes, A.R. et al. (2007) Traffic 8, 259-69.